Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007
Orphan drugs are indicated for the treatment of rare diseases which, in the EU, are defined as those with a prevalence of <5 per 10 000 inhabitants. Characteristically, these diseases negatively affect health-related quality of life and may be life threatening. The EU has passed legislation to encourage pharmaceutical companies to invest in research programmes into rare diseases, with the aim of developing new, safe and effective orphan drugs.
To describe the status of orphan drugs in five countries in the EU (France, Germany, the UK, Italy and Spain), estimate the mean annual cost per patient and indication of these orphan drugs, and determine the associated cost of these drugs in comparison with overall spending on drugs in each country (year 2007 values).
The analysis was limited solely to costs of orphan drugs with sales data available for 2007. The mean annual cost per patient was estimated using recommended regimens for maintenance dose and duration from the summary of product characteristics. Likewise, the ratio between annual costs per patient for treatment of each disease and its prevalence was calculated. Sales data were available for at least one of the countries studied for 38 of the 44 orphan drugs authorized by the European Medicines Agency. Only 21 products had data available for all five countries studied.
Germany was the country with access to the largest number of orphan drugs (36), followed by the UK (34), Spain (28), France (27) and Italy (25). The mean annual cost per patient and indication of the 38 orphan drugs on the market ranged widely from €331 to €337 501. It appears that orphan drugs indicated to treat diseases with a prevalence of <2 per 10 000 inhabitants have higher annual per-patient costs than those indicated to treat diseases with a higher prevalence. The percentage of total drug spending accounted for by orphan drugs in 2007 was 1.7% in France, 2.1% in Germany, 1.0% in the UK, 1.5% in Italy and 2.0% in Spain, with an average overall percentage of 1.7% for these five countries.
In 2007, spending on orphan drugs in five European countries was acceptable in terms of the percentage of these countries’ overall drug expenditure. Mean annual costs per patient of orphan drugs varied widely, with costs being related to the prevalence of the disease for which the product is indicated.
KeywordsSunitinib Rare Disease Annual Cost European Medicine Agency Bosentan
The authors thank Mark Riviere, Guy Rousseau and Frommer Vincent for helping us to review the manuscript. No sources of funding were used to conduct this study or prepare this manuscript. Javier Soto is employed by Pfizer Spain, which commercializes some orphan drugs in the Spanish market. The other authors have no conflicts of interest that are directly relevant to the content of this study.
- 3.European Medicines Agency. Orphan drugs and rare diseases at a glance. London: European Medicines Agency, 2007 Jul 3 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/comp/29007207en.pdf [Accessed 2008 Dec 20]Google Scholar
- 4.European Organisation for Rare Diseases (EURORDIS). EURORDIS position paper on the WHO report on priority medicines for Europe and the world [online]. Available from URL: http://www.eurordis.org/IMG/pdf/eurordis_position_WHO__priority_medicines_dec04.pdf [Accessed 2008 Dec 20]
- 6.European Organisation for Rare Diseases (EURORDIS). Rare diseases: understanding this public health priority. Paris: EURORDIS, 2005 Nov [online]. Available from URL: http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf [Accessed 2008 Dec 20]Google Scholar
- 8.US Department of Health and Human Services, Food and Drug Administration. The orphan drug act (as amended) [online]. Available from URL: http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm [Accessed 2008 Dec 20]
- 9.European Commission. Regulation (EC) No 141/2000 of the European Parliament and of the Council of December 16, 1999 on orphan medicinal products. Official Journal of the European communities 2000; 43(L18): 1–5 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF [Accessed 2008 Dec 20]Google Scholar
- 11.European Medicines Agency. Committee for Orphan Medicinal Products (COMP): overview [online]. Available from URL: http://www.emea.europa.eu/htms/general/contacts/COMP/COMP.html [Accessed 2008 Dec 20]
- 13.European Medicines Agency. European Publics Assessment Reports (EPARs) for authorised medicinal products for human use. 2008 [online]. Available from URL: http://www.emea.europa.eu/htms/human/epar/eparintro.htm [Accessed 2008 Dec 20]Google Scholar
- 14.IMS Health. MIDAS, MAT. Dec 2007 [database]Google Scholar
- 15.European Commission. Enterprise and industry. Community register of orphan medicinal products for human use [online]. Available from URL: http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm [Accessed 2008 Dec 20]
- 16.European Medicines Agency. Human medicines: orphan medicinal products: summaries of opinion on orphan designation [online]. Available from URL: http://www.emea.europa.eu/htms/human/orphans/opinions.htm [Accessed 2008 Dec 20]
- 17.Olry A, editor. Prevalence of rare diseases: bibliographic data. Orphanet report series: rare diseases collection. 2010 May [online]. Available from URL: http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf [Accessed 2008 Dec 20]
- 19.European Medicines Agency. COMP report to the commission in relation to article 10 of regulation 141 /2000 on orphan medicinal products. Doc. Ref. EMEA 35218/2005. London: European Medicines Agency, 2005 Jul 25 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/comp/3521805en.pdf [Accessed 2008 Dec 20]Google Scholar
- 20.Population Reference Bureau. 2007 World population data sheet [online]. Available from URL: http://www.prb.org [Accessed 2008 Dec 20]
- 21.The Association of the British Pharmaceutical Industry. Facts and statistics from the pharmaceutical industry: a global industry. Annual medicines expenditures per person, 2007 [online]. Available from URL: http://www.abpi.org.uk/statistics/section.asp?sect=1#2 [Accessed 2008 Dec 20]Google Scholar
- 22.European Central Bank. Euro foreign exchange reference rates [online]. Available from URL: http://www.ecb.int/stats/exchange/eurofxref/html/index.en.html [Accessed 2008 Dec 20]
- 24.National Institute for Health and Clinical Excellence. Appraising orphan drugs. London: NICE, 2006 [online]. Available from URL: http://www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf [Accessed 2008 Dec 20]Google Scholar
- 25.Gilman BH, Gage B, Haber S, et al. Impact of drug coverage on medical expenditures among the elderly. Health Care Financ Rev 2008; 29(1): 103–18Google Scholar
- 37.National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: NICE [online]. Available from URL: http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf [Accessed 2008 Dec 20]